China Health Management Corp.

China Health Management Corp.

March 10, 2008 16:05 ET

China Health Management Corp.: Olympus Announces Installation and Setup of Minimally Invasive Operating Theatre

LAS VEGAS, NEVADA--(Marketwire - March 10, 2008) - China Health Management Corp. (PINK SHEETS:CNHC) is pleased to announce that its Richland International Hospital (RIH) has received an update from Olympus for the installation and setup of the first Olympus Minimally Invasive Operating Theatre in China at the Richland International Hospital.

Olympus Minimally Invasive Operating Theatre is a state of the art medical system technology, and in order to complete the installation within next two months, Olympus has provided a schedule for the completion of the system. The installation will be in six stages and Olympus will provide technical support and training to the hospital and its staff for three consecutive months to make sure the operation theatre is running effectively.

"We are pleased and honored to be in joint cooperation with a company like Olympus and for a project of this scope, we have full confidence in providing the best healthcare service to our clients in our facility," says Dr. Xu Mei, President of China Health Management and Chairman of Richland International Hospital.

About China Health Management Corp.

China Health Management Corp. is a healthcare management company focused on Operations and Management of hospitals in China. The company's first target is to become the leader in the high-end healthcare and medical services industry in Kunming city, Yunnan Province, China.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact Information